Ravulizumab
Ravulizumab is a pharmaceutical drug with 43 clinical trials. Currently 14 active trials ongoing. Historical success rate of 66.7%.
Success Metrics
Based on 16 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
7
Mid Stage
29
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
66.7%
16 of 24 finished
33.3%
8 ended early
14
trials recruiting
43
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
Clinical Trials (43)
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
Real-life Treatment Outcomes of Ravulizumab in PNH
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
Ravulizumab Outcomes in Polish Patients With aHUS
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 43